1/1
7 files

Real World Evidence for Oritavancin Use in Gram-Positive Infections

media
posted on 02.07.2020 by Mark Redell, Sandy Estrada, Thomas P. Lodise, Glenn S Tillotson, Dino Delaportas, Lauren E. Brownell, Meagan L. Adamsick, Erin K. McCreary, Joshua P. Vanderloo, Erika J. Ernst, Emily R. Jackson, Lucas T. Schulz, Brittany Helton, Ashley MacWhinnie, Sarah Brooks Minor, Kelly D. Rafferty, Steven L. Allison, Cristen Whittaker, Ethan Nhan, Joseph Reilly, Warren E. Rose, Paul R. Hutson, Nicholas W. Van Hise, Vishnu Chundi, Vishal Didwania, Michael Anderson, David McKinsey, Ingrid Roig, Akhilesh Sharma, Russell M. Petrak, Patrick J. Scoble

Article full text

These articles are part of a supplement to Drugs – Real World Outcomes titled “Real World Evidence for Oritavancin Use in Gram-Positive Infections” wholly funded by Melinta Therapeutics. You can find the supplement here.

The above summary slides represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full texts online (see “read the peer-reviewed publication” opposite).

© The authors, CC-BY-NC 2020.

History

Exports